First-line ibrutinib plus venetoclax achieved a 69% complete response rate in patients with nonblastoid mantle cell lymphoma (MCL) aged ≥65 years or harboring TP53 mutations.
Median progression-free survival reached over 40 months in patients ≥65 years without TP53 mutation, with durable remissions sustained up to 3 years.
Safety profile was manageable, with diarrhea, fatigue, neutropenia, and COVID-19 as the most common adverse events.
This chemotherapy-free regimen offers a promising option for high-risk or elderly MCL patients traditionally challenged by poor prognosis.
